Humanized anti-novel coronavirus neutralizing antibody nCoV-61 and application thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- WUHAN INST OF BIOLOGICAL PROD CO LTD
- Publication Date
- 2021-03-02
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of biotechnology, in particular, to a human-derived anti-new coronavirus neutralizing antibody nCoV-61 and its application. Background technique
[0002] The novel coronavirus SARS-CoV-2 is a new virus discovered in 2019 that can cause viral pneumonia, or lung infection, in humans. The coronavirus genome sequentially encodes the spike protein, envelope protein, membrane protein and nucleocapsid protein. Among them, the spike protein (Spike) is the most important surface membrane protein of coronavirus, which contains two subunits S1 and S2, of which S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the receptors of cells. The SARS-CoV-2 spike protein interacts with human angiotensin-converting enzyme 2 (ACE2) to infect human respiratory epithelial cells.
[0003] Although multiple drugs such as remdesivir, hydroxychloroquine, lopinavir, and interferon β1a have been proven to ...